Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)
2.200
-0.070 (-3.08%)
Aug 27, 2026, 4:08 PM HKT
HKG:2185 Revenue
Shanghai Bio-heart Biological Technology had revenue of 24.07M CNY in the half year ending December 31, 2025. This brings the company's revenue in the last twelve months to 38.45M, up 84.29% year-over-year. In the year 2025, Shanghai Bio-heart Biological Technology had annual revenue of 44.93M.
Revenue (ttm)
38.45M CNY
Revenue Growth
+84.29%
P/S Ratio
12.45
Revenue / Employee
591.49K CNY
Employees
65
Market Cap
552.56M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.93M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 586.21M |
| 3D Medicines | 396.26M |
| Cutia Therapeutics | 374.07M |
| JW (Cayman) Therapeutics Co. | 315.65M |
| Wuhan YZY Biopharma | 74.40M |
| Brii Biosciences | 40.23M |
| Kintor Pharmaceutical | 36.37M |
| Transcenta Holding | 8.27M |